Lisata Therapeutics (NASDAQ:LSTA) Releases Earnings Results

Posted by Geri Gentry on May 13th, 2026

Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, FiscalAI reports.

Lisata Therapeutics Price Performance

LSTA stock traded up $0.04 during midday trading on Wednesday, reaching $3.30. 13,903 shares of the stock were exchanged, compared to its average volume of 142,064. The stock has a market capitalization of $30.01 million, a PE ratio of -1.77 and a beta of 0.81. Lisata Therapeutics has a 52 week low of $1.81 and a 52 week high of $5.07. The company has a fifty day moving average price of $4.30 and a 200 day moving average price of $3.35.

Institutional Trading of Lisata Therapeutics

A number of hedge funds have recently made changes to their positions in LSTA. SOL Capital Management CO acquired a new position in Lisata Therapeutics in the 1st quarter valued at approximately $61,000. Cerity Partners LLC bought a new stake in Lisata Therapeutics in the second quarter worth approximately $32,000. CIBC Bancorp USA Inc. bought a new stake in shares of Lisata Therapeutics in the 3rd quarter valued at $37,000. Ground Swell Capital LLC bought a new stake in Lisata Therapeutics in the third quarter valued at $62,000. Finally, Deltec Asset Management LLC bought a new stake in Lisata Therapeutics in the 1st quarter valued at about $451,000. 8.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. downgraded Lisata Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $15.00.

View Our Latest Stock Analysis on LSTA

Lisata Therapeutics Company Profile

(Get Free Report)

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.